Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. 8-K earnings release, 10-Q stay in one workspace.
Earnings call · FY2022 Q2
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Executive readout · one minute
Read the call alongside every captured source. 8-K earnings release, 10-Q stay in one workspace.
Forward guidance
6 guided metrics
Management's latest ranges and targets are included below.
Research coverage
2 live sources
Open each available source without leaving this research workspace.
Open the source you need; every reader stays inside this workspace.
From the 8-K filed Jul 26, 2022.
| Metric | Period | Guided | Basis |
|---|---|---|---|
|
Revenues
2022 outlook
|
$15B – $15.6B | Non-GAAP | |
|
COPAXONE revenues
Lowered
2022 outlook
|
$700M | — | |
|
Adjusted EBITDA
Maintained
2022 outlook
|
$4.7B – $5B | Non-GAAP | |
|
Non-GAAP diluted EPS
Maintained
2022 outlook
|
$2.40 – $2.60 | Non-GAAP | |
|
Free cash flow
Maintained
2022 outlook
|
$1.9B – $2.2B | — | |
|
Non-GAAP tax rate
2022 outlook
|
13% – 14% | Non-GAAP |
How the reported period landed and where the business moved.
SEC filing · Item 2.02
Filed Jul 26, 2022 · complete as-filed document
SEC periodic report
Filed Jul 27, 2022 · complete as-filed document